Abstract 913
Background
The primary APACT analysis showed no significant difference in disease-free survival (DFS) by blinded, independent radiologic review with nab-P/G vs G in patients (pts) with surgically resected pancreatic cancer (PC). However, investigator-assessed DFS (prespecified sensitivity analysis) and interim overall survival (OS; secondary endpoint) trended in favor of nab-P/G. Here, we report interim OS exploratory subanalyses.
Methods
Treatment-naive pts with histologically confirmed PC, macroscopic complete resection (R0/R1), CA 19-9 < 100 U/mL, and ECOG PS 0 or 1 were enrolled. Stratification factors included resection (R0/R1), lymph node (LN) status (positive [+]/negative), and geographic region. Pts were treated ≤ 12 weeks after surgery with nab-P 125 mg/m2 + G 1000 mg/m2 or G 1000 mg/m2 alone on days 1, 8, and 15 every 28 days for 6 cycles. For the primary endpoint assessment, independent reviewers received only baseline clinical data and scans. OS and safety were secondary endpoints. Ten prespecified subanalyses were performed.
Results
866 pts were randomized. Median age was 64 y (range, 34–86); most were male (56%) and white (78%) and had ECOG PS 0 (60%), LN+ status (72%), and R0 resection (76%). At the original data cutoff (31 December 2018; median follow-up, 38.5 mo), median OS (interim) trended in favor of nab-P/G vs G (40.5 vs 36.2 mo; HR 0.82; 95% CI, 0.680 - 0.996; nominal P = 0.045). Pts with poor characteristics had numerically longer median OS with nab-P/G vs G: 32.5 vs 27.0 mo in pts with R1 resection (n = 105 and 100) and 33.8 vs 28.9 mo in pts with LN+ status (n = 311 and 312). This is consistent with the median OS observed with nab-P/G vs G in pts whose tumors were < 1 mm to the closest margin (32.5 vs 29.7 mo; n = 114 and 112). Pts with both R1 resection and LN+ status had numerically longer median OS with nab-P/G vs G (30.7 vs 24.9 mo; n = 87 and 83).
Conclusions
Final OS data may clarify the role for adjuvant nab-P/G. Interim OS analyses suggest that continued investigation of adjuvant nab-P/G for pts with suboptimally resected PC or who may not tolerate FOLFIRINOX is warranted.
Clinical trial identification
NCT01964430.
Editorial acknowledgement
Rebecca Tweedell, MediTech Media, Ltd, funded by Celgene Corporation.
Legal entity responsible for the study
The authors.
Funding
Celgene Corporation.
Disclosure
M.A. Tempero: Advisory / Consultancy: AbbVie, Inc., Advance Medical, Inc., BioPharm Communications, Bristol-Myers Squibb, Celgene Corporation, Eisai, Inc., Ignyta, Inc., Pharmacyslics, LLC., Pharmcyte Biotech, Tocagen, Inc., Immunovia, CPRIT, AstraZeneca. M. Reni: Research grant / Funding (self): Celgene, Baxalta, Merck Serono, Helsinn; Non-remunerated activity/ies: Celgene, Baxalta, Merck Serono, Lilly, Pfizer, AstraZeneca, Novocure, Halozyme, Novartis, Shire. H. Riess: Speaker Bureau / Expert testimony: Celgene, Roche, Shire; Advisory / Consultancy: Celgene, Shire. E.M. O’Reilly: Honoraria (self), Research grant / Funding (institution): Celgene Corporation; Research grant / Funding (self): ActaBiologica, Agios, Array, AstraZeneca, Bayer, Beigene, BMS, Casi, Exelixis, Genentech, Halozyme, Incyte, Lilly, Mabvax, Novartis, OncoQuest, Polaris Puma, QED, Roche. S. Krishnamurthi: Non-remunerated activity/ies, Research Funding: Taiho, CytomX, Regeneron, Celgene, AbbVie. P. Österlund: Advisory / Consultancy: Amgen; Bayer; Celgene; Eisai; Lilly; Merck Serono; Roche; Sanofi; Servier/Shire; Speaker Bureau / Expert testimony: Prime Oncology; Research grant / Funding (institution): Amgen (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Lilly (Inst); Merck Serono (Inst); MSD (Inst); Nordic Drugs (Inst); Roche (Inst); Sanofi (Inst); Servier (Inst); Travel / Accommodation / Expenses: AbbVie, Pierre Fabre. M. Milella: Advisory / Consultancy: Pfizer; Speaker Bureau / Expert testimony: AstraZeneca, EUSA Pharma. S. Siena: Advisory / Consultancy: Amgen, Bayer, BMS, CheckmAb, Celgene, Daiichi-Sankyo, Incyte, Merck, Novartis, Roche-Genentech, and Seattle Genetics. J. Tabernero: Advisory / Consultancy, Personal Financial Interest: Array Biopharma, AstraZeneca, Bayer, BeiGene, Boehringer Ingelheim, Chugai, Genentech, Inc., Genmab A/S, Halozyme, Imugene Limited, Inflection Biosciences Limited, Ipsen, Kura Oncology, Lilly, MSD, Menarini, Merck Serono, Merrimack, Merus, Molecular Part. E. Van Cutsem: Advisory / Consultancy: Bayer, Lilly, Roche, Servier, Bristol-Myers Squibb, Celgene, Merck Sharp & Dohme, Merck KGaA, Novartis, AstraZeneca; Research grant / Funding (self): Amgen, Bayer, Boehringer Ingelheim, Lilly, Novartis, Roche, Celgene, Ipsen, Merck, Merck KGaA, Servier, Bristol-Myers Squibb. P.A. Philip: Research grant / Funding (self): Celgene, Bayer, and Incyte; Speaker Bureau / Expert testimony: Roche, Sanofi, and Amgen; Advisory / Consultancy: Celgene Corporation. D. Goldstein: Advisory / Consultancy, Research grant / Funding (institution): Celgene Corporation, Pfizer. J.D. Berlin: Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Celgene Corporation. M. Li: Shareholder / Stockholder / Stock options, Full / Part-time employment: Celgene Corporation. S. Ferrara: Shareholder / Stockholder / Stock options, Full / Part-time employment: Celgene Corporation. Y. Le Bruchec: Shareholder / Stockholder / Stock options, Full / Part-time employment: Celgene Corporation. D. McGovern: Shareholder / Stockholder / Stock options, Full / Part-time employment: Celgene Corporation. A. Biankin: Leadership role: Gene Forward Inc; Research grant / Funding (self): Celgene, AstraZeneca; Licensing / Royalties: Agilent; Honoraria (self): Celgene, AstraZeneca, Tusk, Astar; Travel / Accommodation / Expenses: Celegene, AstraZeneca, Roche; Speaker Bureau / Expert testimony: Celgene, AstraZeneca, Tusk, Astar, Roche. All other authors have declared no conflicts of interest.
Resources from the same session
1109 - First Canadian Interim Analysis from the Phase IIIb CompLEEment-1 Ribociclib + Letrozole HR+ HER2- Advanced Breast Cancer Trial
Presenter: Cristiano Ferrario
Session: Poster Display session 2
Resources:
Abstract
4401 - Real-world effectiveness of first-line palbociclib + letrozole for metastatic breast cancer 4 years post approval in the US
Presenter: Jonathan Kish
Session: Poster Display session 2
Resources:
Abstract
5876 - Palbociclib-Fulvestrant (PALBO-FUL) and Everolimus -Exemestane (EVE-EXE) for Second line Hormonal Treatment (HT) of Metastatic Breast Cancer (MBC) with Lobular Histology: a Propensity Score Matched Analysis of a Multicenter ‘Real-World’ Patients (pts) Series.
Presenter: Armando Orlandi
Session: Poster Display session 2
Resources:
Abstract
3587 - Dose-escalation study of G1T48, an oral selective estrogen receptor degrader (SERD), in postmenopausal women with ER+/HER2- locally advanced or metastatic breast cancer (ABC)
Presenter: E Dees
Session: Poster Display session 2
Resources:
Abstract
5696 - Final results of the STEM trial: SFX-01 in the Treatment and Evaluation of ER+ Her2- Metastatic breast cancer (mBC)
Presenter: Sacha Howell
Session: Poster Display session 2
Resources:
Abstract
1475 - Alpelisib (ALP) + Fulvestrant (FUL) in Hormone-Receptor Positive (HR+), Human Epidermal Growth Factor Receptor-2–Negative (HER2–) Advanced Breast Cancer (ABC): Subgroup Analysis by Presence of Visceral Metastasis (VM) in the SOLAR-1 Trial
Presenter: Mario Campone
Session: Poster Display session 2
Resources:
Abstract
2549 - Phase 1 Dose Escalation Study of a Selective Androgen Receptor Modulator RAD140 in Estrogen Receptor Positive (ER+), HER2 Negative (HER2-) Breast Cancer (BC)
Presenter: Erika Hamilton
Session: Poster Display session 2
Resources:
Abstract
3787 - A Phase I study of XZP-3287, a novel oral CDK4/6 Inhibitor, administered on a continuous dosing schedule, in patients with advanced solid tumours
Presenter: Binghe Xu
Session: Poster Display session 2
Resources:
Abstract
4835 - Phase-I dose-escalation and expansion study of the PARP inhibitor, fluzoparib (SHR3162), in patients with advanced solid tumors
Presenter: Huiping Li
Session: Poster Display session 2
Resources:
Abstract
5083 - Phase 2 study of DHP107 (Liporaxel®, oral paclitaxel) in first-line, HER2 negative recurrent/metastatic breast cancer (OPTIMAL study, NCT03315364)
Presenter: Jin-Hee Ahn
Session: Poster Display session 2
Resources:
Abstract